Videos

Managing Relapses in Patients With Multiple Sclerosis

A multiple sclerosis expert, Dr Darin Okuda reviews long-term outcomes with ozanimod in DAYBREAK trial based on the number of relapses that was presented at EAN 2022.

Darin Okuda, MD

Gaps in Care in Myasthenia Gravis and Take-Home Points

Dr Darin Okuda discusses strategies for treatment selection and management of relapses in multiple sclerosis.

Ericka Wong, MD

Zilucoplan and Other Pipeline Agents in the Treatment of Myasthenia Gravis

Ericka Wong, MD, comments on gaps in care in myasthenia gravis and provides take-home messages for physicians treating patients with this condition.

Ericka Wong, MD

Using Nonamnestic Cognitive Symptoms to Predict Trajectories of Neurodegenerative Disorders: Jagan A. Pillai, MD, PhD

An expert neurologist discusses zilucoplan and other pipeline agents in the treatment of myasthenia gravis.

Jagan A. Pillai, MD, PhD

Formulating the Right Combination of Acoustic Metrics to Quantify Cognitive Impairment: Alvaro Pascual-Leone, MD, PhD

The neurologist at Cleveland Clinic’s Lou Ruvo Center for Brain Health detailed new findings on whether initial cognitive symptoms have similar rates of functional decline across a handful of neurodegenerative disorders. [WATCH TIME: 3 minutes]

Alvaro Pascual-Leone, MD, PhD

Using Neurofilaments as a Biomarker in MS

The chief medical officer and cofounder of Linus Health provided background on the reasoning for the measures used in a new machine learning algorithm that classifies cognitive status. [WATCH TIME: 3 minutes]

Stephen Krieger, MD;Heidi Crayton, MD;Jacqueline Nicholas, MD, MPH;Flavia Nelson, MD

Safety Considerations and Monitoring for S1P Modulators in MS

Dr Jacqueline Nicholas hypothesizes about the utility of neurofilaments as a biomarker of disease severity in patients with multiple sclerosis.

Stephen Krieger, MD;Heidi Crayton, MD;Jacqueline Nicholas, MD, MPH;Flavia Nelson, MD

History and Future Outlook of V236E and R251G Missense Variants in Alzheimer disease: Yann Le Guen, PhD

Heidi Crayton, MD, and Jacqueline Nicholas, MD, review the importance of long-term safety data in the management of patients with multiple sclerosis, and Flavia Nelson, MD, discusses her approach to counseling patients on the safety considerations regarding new S1P modulating agents.

Yann Le Guen, PhD

Using Machine Learning, Speech Production to Quantify Mild Cognitive Impairment: Alvaro Pascual-Leone, MD, PhD

The assistant director of computational biology at Stanford University discussed the knowns and unknowns of 2 rare missense variants and their associations with decreased Alzheimer disease risk. [WATCH TIME: 4 minutes]

Alvaro Pascual-Leone, MD, PhD

August 2nd 2022

AUPN Leadership Minute Episode 24: How Much Is a Neurologist Worth: Factoring the Downstream

The medical director of the Deanna and Sidney Wolk Center for Memory Health provided background on his new study using multimodal digital biomarkers to classify patients with mild cognitive impairment. [WATCH TIME: 5 minutes]

Alissa Willis, MD;Joseph R. Berger, MD

August 1st 2022

Complexities With SMN2 Copies in Spinal Muscular Atrophy: Basil Darras, MD

Episode 24 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Joseph R. Berger, MD, of the University of Pennsylvania. [WATCH TIME: 7 minutes]

Basil Darras, MD

August 1st 2022

Examining the Association of APOE Missense Variants and the Risk of Alzheimer Disease: Yann Le Guen, PhD

The associate neurologist-in-chief at Boston Children’s Hospital discussed the 4-copy conundrum and whether treatment decisions differ based on SMN2 copies for patients with spinal muscular atrophy. [WATCH TIME: 2 minutes]

Yann Le Guen, PhD

July 31st 2022

FDA Accepts NDA for Tofersen, Serious Falls Increased With Hypnotic Medications, Racial Disparities in Sleep of Pregnant Women

The assistant director of computational biology at Stanford University provided background on recent findings of two rare APOE missense variants and reduced risk of Alzheimer disease associated with them. [WATCH TIME: 4 minutes]

NeurologyLive® Staff

July 30th 2022

Approaching Treatment for LGS

Neurology News Network for the week ending July 30, 2022. [WATCH TIME: 4 minutes]

Joseph Sullivan, MD;Kelly Knupp, MD;Mary Anne Meskis;Tracy Dixon-Salazar, PhD

Joseph Sullivan, MD;Kelly Knupp, MD;Mary Anne Meskis;Tracy Dixon-Salazar, PhD

Kelly Knupp, MD, provides insight on optimizing treatment for patients with Lennox-Gastaut Syndrome.

Newer Treatments for LGS

Implications of Ozanimod Discontinuation Data for MS Care

Dr Kelly Knupp examines data on fenfluramine and cannabidiol for the management of Lennox-Gastaut Syndrome.

Wallace Brownlee, MBChB, PhD, FRACP

Relapse Following Discontinuation of Ozanimod

Dr Brownlee shares his advice and recommendations from national MS society on providing cognitive care for patients suffering from MS.

Wallace Brownlee, MBChB, PhD, FRACP

Treatment Discontinuation in Multiple Sclerosis

A multiple sclerosis expert, Dr Brownlee shares study design and clinical data on relapse following discontinuation of ozanimod in patients with multiple sclerosis.

Wallace Brownlee, MBChB, PhD, FRACP

The Amyloid Cascade Hypothesis and Encouraging New Methods for Alzheimer Drug Development: Ralph Nixon, MD, PhD

Dr Wallace Brownlee discusses reasons of and clinical impact of treatment discontinuation in multiple sclerosis.

Ralph Nixon, MD, PhD

Surgical Considerations for Patients With MS

The professor of psychiatry and cell biology at NYU Langone provided insight on the reaction to a new paper that challenges how traditional drug development has approached Alzheimer disease. [WATCH TIME: 4 minutes]

Jeffrey Dunn, MD;Regina Berkovich, MD, PhD

Patient Education in Ethnically Diverse and Underrepresented MS Patients

Experts in neurology discuss the considerations and practicalities of treating patients with multiple sclerosis who may undergo surgery and explore the role of treatment holidays.

Jeffrey Dunn, MD;Regina Berkovich, MD, PhD

Mechanistic Potential of Taldefgrobep Alfa in Spinal Muscular Atrophy: Lindsey Lee Lair, MD

Regina Berkovich, MD, PhD, comments on the role of patient education in engaging ethnically diverse and underrepresented patient populations with multiple sclerosis in their treatment plans.

Lindsey Lee Lair, MD

Clinical Trial Design Considerations for MS

The vice president of clinical development at Biohaven shed light on a newly initiated phase 3 study evaluating a promising agent for patients with all types of spinal muscular atrophy. [WATCH TIME: 2 minutes]

Scott Newsome, DO, MSCS, FAAN;Lawrence Steinman, MD;Ahmed Obeidat, MD, PhD;Amit Bar-Or, MD, FRCPC;Bridget A. Bagert, MD, MPH

Considering Vaccination for Various MS Patient Populations

Experts in neurology comment on clinical trial design considerations and discuss novel imaging techniques and biomarkers that they consider most important to investigate for multiple sclerosis.

Scott Newsome, DO, MSCS, FAAN;Lawrence Steinman, MD;Ahmed Obeidat, MD, PhD;Amit Bar-Or, MD, FRCPC;Bridget A. Bagert, MD, MPH

Shared Decision-Making in Migraine Management

Bridget A. Bagert, MD, leads a discussion on the ideal patient populations for using a potential vaccine for multiple sclerosis, and the panel comments on other factors to consider when administering vaccines.

Kita Williams, MD

Nonpharmacological Options and Lifestyle Changes for Migraine Management

Dr Williams discusses the role of shared decision-making in treating patients with migraines.

Kita Williams, MD